Tag Archives: PCMI

Top 10 Low Price Stocks To Invest In 2018

The U.S. Commerce Department backed Boeing in its challenge to Bombardier, recommending an enormous tariff on sales of Bombardier’s C Series jetliner, a major blow to the Canadian plane maker.

The initial ruling by the International Trade Commission, an arm of the Commerce Department, recommends a 219.63% tariff on the delivery of each airliner, according to a person briefed on the ITC’s findings.

Boeing (BA), America’s largest exporter and sole U.S. producer of commercial airliners, is suing Bombardier. At issue is whether Bombardier received financial backing from the Canadian government that allowed the plane maker to stay afloat and sell to Delta for what Boeing alleges were “absurdly low prices.”

“The U.S. values its relationships with Canada, but even our closest allies must play by the rules,” said Commerce Secretary Wilbur Ross in a statement. “The subsidization of goods by foreign governments is something that the Trump Administration takes very seriously, and we will continue to evaluate and verify the accuracy of this preliminary determination.”

Top 10 Low Price Stocks To Invest In 2018: NXP Semiconductors N.V.(NXPI)

Advisors’ Opinion:

  • [By Sreekanth Anasa]

    The acquisition of NXP Semiconductor (NSDQ:NXPI) has opened up multi-billion dollar connected devices market from smartphone to car to home, for Qualcomm. It seems prepared to cater to the massive connected devices market in terms of OS preference with Android and Windows 10 mobile collaborations. Though Amazon and its AWS have different take on cloud and IoT devices with its Greengrass solution which revolves around the cloud and aggregation of sensors.

  • [By Anders Bylund]

    NXP Semiconductors (NASDAQ:NXPI) is closing out 2016 with a 16% return for the full year. Here’s what to expect out of the Netherlands-based embedded chip maker in 2017.

  • [By Sreekanth Anasa]

    While Qualcomm continues to work on closing its $47 billion acquisition of automotive chipmaker NXP Semiconductor (NSDQ:NXPI), at the CES 2017, NXP showcased why the company is a major force in automotive computing.At the show, NXP partnered with several companies to demonstrate a “collective vision of safe and secure end-to-end mobility through a highly automated driving demonstration and experience.” NXP also demonstratedits so-called RoadLINK platform in collaboration with automotive parts giant Delphiand privately held start-up Savari, highlighting the traffic safety improvements one can achieve through the platform.

  • [By Sreekanth Anasa]

    This has the potential to offset the sluggishness in demand of smartphone chips around the world. Also, certain performance benchmarks of Qualcomm’s latest flagship processor 835 are making positive waves. A lot is riding on Qualcomm’s $47B acquisition of NXP Semiconductor (NASDAQ:NXPI), which it plans to complete by the end of the year. This acquisition would open up the high potential IoT segment as well for the smartphone chipmaker. All of these positives have been overshadowed by Qualcomm Inc’s legal troubles, which could hit its licensing business hard. Qualcomm depends heavily on its licensing business to generate bulk of its pre-tax profits. In the most recent fiscal year, Qualcomm’s QTL segment accounted for 78% of its pre-tax profits. The verdicts in the legal issues faced by Qualcomm will not be out anytime soon. These tend to be long drawn courtroom battles, and have cast a spell of uncertainty over Qualcomm’s licensing business.

Top 10 Low Price Stocks To Invest In 2018: Nuveen Municipal Value Fund Inc.(NUV)

Advisors’ Opinion:

  • [By Donald van Deventer]

    The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:

Top 10 Low Price Stocks To Invest In 2018: Bed Bath & Beyond Inc.(BBBY)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Trey Thoelcke]

    Bed Bath & Beyond Inc. (NASDAQ: BBBY) is scheduled to report its fiscal third-quarter results after trading ends on Wednesday. The consensus analyst estimates are $0.99 in EPS and revenue of $3.01 billion. Shares ended trading on Friday at $47.27. The consensus price target is $42.76. The 52-week range is $38.60 to $52.71.

  • [By Peter Graham]

    A long term performance chart shows Williams-Sonoma still in positive territory along with Restoration Hardware Holdings Inc (NYSE: RH) while Bed Bath & Beyond Inc (NASDAQ: BBBY) and Pier 1 Imports Inc (NYSE: PIR) have been underperforming for some time:

  • [By WWW.THESTREET.COM]

    Shares of Bed Bath & Beyond (BBBY) took a bath today, Cramer told viewers, and is likely beyond hope.

    The home-goods retailer posted a huge earnings miss, delivering just 53 cents a share when the analysts were expecting 66 cents a share. Making matters worse, the company also saw a 2% decline in same-store sales.

Top 10 Low Price Stocks To Invest In 2018: DSP Group Inc.(DSPG)

Advisors’ Opinion:

  • [By Lisa Levin]

    Technology shares rose by 2 percent in the US market on Friday. Top gainers in the sector included Fabrinet (NYSE: FN), and DSP Group, Inc. (NASDAQ: DSPG).

Top 10 Low Price Stocks To Invest In 2018: AxoGen, Inc.(AXGN)

Advisors’ Opinion:

  • [By Lisa Levin]

    AxoGen, Inc. (NASDAQ: AXGN) was down, falling around 10 percent to $22.42. AxoGen reported a proposed public offering of common stock.

    Commodities

Top 10 Low Price Stocks To Invest In 2018: Durect Corporation(DRRX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.

Top 10 Low Price Stocks To Invest In 2018: PCM, Inc.(PCMI)

Advisors’ Opinion:

  • [By Lisa Levin]

    PCM Inc (NASDAQ: PCMI) was down, falling around 26 percent to $14.63. PCM reported Q2 adjusted earnings of $0.47 per share on sales of $560.1 million.

Top 10 Low Price Stocks To Invest In 2018: The Blackstone Group L.P.(BX)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Of the ten PE companies that I follow, Blackstone Group LP (BX) is by far and away the largest publicly traded private equity partnership with a $35 billion market cap, but also the best positioned to benefit from all the catalysts noted within.

  • [By WWW.THESTREET.COM]

    SeaWorld Entertainment (SEAS) is probably the most famous example of a company that’s suffered from animal cruelty allegations. Shares of the theme park operator, backed by Blackstone (BX) , have never recovered from the release of the 2013 documentary Blackfish, which argued that orca captivity is inhumane and dangerous to the human trainers of the orcas. SeaWorld announced in March that it would phase out its orca captivity, breeding and live shows. The company’s remaining whales, most of which were born in captivity, will live out their lives at the parks. The news sent SeaWorld shares soaring 9%, but continued attendance drops forced the company to slash its dividend and invest $175 million in new attractions.

  • [By Dan Caplinger]

    NCR’s first-quarter results were solid and continued the company’s positive momentum. Sales were up 2% to $1.48 billion, and while that was only a small gain, it was larger than the 1% rise that most investors were expecting. On a GAAP basis, NCR lost money during the quarter, but after excluding impacts from the company’s transaction with Blackstone Group (NYSE:BX), adjusted earnings of $0.56 per share were up by nearly half from year-ago levels and were stronger than the $0.46 per share consensus forecast among those following the stock.

Top 10 Low Price Stocks To Invest In 2018: Heartware International, Inc.(HTWR)

Advisors’ Opinion:

  • [By Spencer Israel]

    4. HeartWare International Inc (NASDAQ: HTWR) – The heart device maker agreed to be acquired by Medtronic for $58 per share in cash two weeks ago. Prior to that the stock had been trading just above $30. 

Top 10 Low Price Stocks To Invest In 2018: Pershing Gold Corporation(PGLC)

Advisors’ Opinion:

  • [By Sara Cornell]

    Leading the way is CEO Edward Karr. As a founder of Pershing Gold Corp (NASDAQ:PGLC), he currently serves on their Board of Directors, and has been active in the natural resource industry for many years. With a background in finance and investment banking, Karr is credited with raising capital to begin operations at US Gold Corp, and establishing financing for both the operational and exploration sides of the company.

stock companies

In a stunning reversal, the Trump administration will not seek to further delay an Obama-era investment rule designed to put an end to costly, conflict-filled retirement advice.

The so-called fiduciary rule will require anyone selling retirement investment advice to put their clients’ interests first and to plainly disclose fees. It was set to take partial effect on April 10, but the incoming Trump administration had forced a delay until June 9.

stock companies: Abengoa Yield plc(ABY)

Advisors’ Opinion:

  • [By Jim Robertson]

    I’ve included a daily chart below of both DRN, the primary ETF tracking real estate REITS, and Atlantica Yield plc (ABY), a utility Company that owns a portfolio of contracted renewable energy, power generation, electric transmission, and water assets in North America, South America, and EMEA.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

  • [By Jared Kimball]

    But what does this apparent shift within the top levels of the nation’s executive milieu mean for the country’s growing renewable energy sector, and what do the new administration’s promises to redirect its efforts toward fossil fuels mean for investors in renewables? Let’s take a look at London-based Atlantica Yield PLC (NASDAQ:ABY)—formerly Abengoa Yield PLC (NASDAQ:ABY)—and how its fortunes have fared during this period of legislative uncertainty and the resulting speculation on the part of investors in the sector.

stock companies: PCM, Inc.(PCMI)

Advisors’ Opinion:

  • [By Lisa Levin]

    PCM Inc (NASDAQ: PCMI) was down, falling around 26 percent to $14.63. PCM reported Q2 adjusted earnings of $0.47 per share on sales of $560.1 million.

stock companies: Abertis Infraestructuras S.A. (ABFOF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Atlantia (ATASF) (AT.IM), Eiffage (OTCPK:EFGSY) (FGR.FP), Ferrovial (OTC:FRRVF) (FER.SM), Albertis (OTC:ABFOF) (ABE.SM) and Vinci (OTCPK:VCISF) (DG.FP)

stock companies: Paragon Offshore plc (PGNPQ)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Paragon Offshore’s (OTCPK:PGNPQ) former management’s audacious efforts to omit parts of the senior secured lenders by deeming them unimpaired and instead pay out the majority of the company’s cash to junior unsecured bondholders by presenting a set of entirely unrealistic business forecasts to the court. Fortunately, in case of Paragon Offshore, the bankruptcy judge recognized the framing and accordingly denied confirmation of the company’s plan of reorganization, effectively sending Paragon Offshore back to the drawing board. Consequently, management was ousted after the failure. I have covered the Paragon Offshore saga in a series of articles over the past few quarters, so interested investors might want to take a look at this highly fascinating and still evolving case study.

  • [By SEEKINGALPHA.COM]

    With even brand new rigs struggling to find work, the jig was soon up for owners of old equipment, like Paragon Offshore (OTCPK:PGNPQ), which is currently undergoing its second debt restructuring in less than three years of independent existence. Likewise, drillers with a fondness for aggressive use of debt were soon in trouble, most notably, former high-flier Seadrill (SDRL) and its little brother North Atlantic Drilling (NADL), which will no doubt file for restructuring within months. As a consequence of the crisis, the OSD industry now has a number of participants without a large debt burden, either new entrants like Borr Drilling, or established competitors that have had debt reduced in a restructuring, such as Ocean Rig (ORIG), to be followed within this year by others, almost certainly including each of SDRL, NADL, and Pacific Drilling (PACD).

stock companies: Sina Corporation(SINA)

Advisors’ Opinion:

  • [By Steve Symington]

    Shares ofSINA Corporation(NASDAQ:SINA)rose 25.8% in 2016,according to data from S&P Global Market Intelligence, following a pair of stronger-than-expected quarterly reports from the Chinese internet leader in the second half.

  • [By Leo Sun]

    Warren Buffett famously told investors to be “fearful when others are greedy, and greedy when others are fearful.” Dedicated followers of that mantra would probably dismiss Chinese online media giant SINA (NASDAQ:SINA) — which rallied 120% over the past 12 months to a six-year high — as a “greedy” play.

  • [By Ezra Schwarzbaum]

    It was quickly followed by two other Chinese social media sites: SINA Corp (NASDAQ: SINA) and Momo Inc (ADR) (NASDAQ: MOMO).

    Weibo Responds

    Weibo issued a press release later in the day saying it would cooperate with the State Administration of Press, Publication, Radio, Film and Television.

  • [By Shanthi Rexaline]

    SINA Corp (NASDAQ: SINA), which has a stake in Weibo, also tumbled.

    Weibo confirmed that the State Administration of Press, Publication, Radio, Film and Television of the People’s Republic of China or SAPPRFT has ordered local authorities to take measures to suspend audio and video services of some internet companies.

investing in the stock market

The notion that value outperforms in the long run is a staple in the financial literature, and for an obvious reason: the historical record tells us so. But the last nine years tell a different story, based on the return spread for the Russell 1000 Value Index less the Russell 1000 Growth Index. As AJO Partners in Philadelphia advised in an investment note last week, the current run of growth’s outperformance in the US large-cap space is the longest period of superior results over value since the history of the Russell indexes, which dates to the 1970s.

Growth’s enduring out-performance isn’t a total surprise, according to AJO. In the previous run of value’s sub-par run, growth dominated for roughly seven years, courtesy of a tech bubble that rendered value investing null and void for an extended stretch.

investing in the stock market: Viacom Inc.(VIA)

Advisors’ Opinion:

  • [By Keith Noonan]

    While 2016 played host to a range of films that underperformed, the biggest flops belonged to Disney (NYSE:DIS), Viacom (NASDAQ:VIA) (NASDAQ:VIAB) and Lions Gate Entertainment (NYSE:LGF.A). Click through the presentation below to get the details on the year’s five biggest film flops and to learn what last year’s movie misfires mean for the companies involved.

  • [By Douglas A. McIntyre]

    The Pillsbury Doughboy is the mascot of the Pillsbury Company, which is owned by General Mills (NYSE: GIS) and J.M. Smucker (NYSE: SJM). The Doughboy was created by Pillsburys advertising agency almost 50 years ago. Pikachu are characters owned by The Pokemon Company International and appear in card games, video games, TV shows, movies and comic books. Founded in 1998, the Japanese company has achieved total games sales of almost 280 million. SpongeBob SquarePants was created for Nickelodeon, which is owned by Viacom (NASDAQ: VIA). The show premiered in 1999 and has spawned movies, video games and theme park rides. Ronald McDonald is a c

investing in the stock market: Actinium Pharmaceuticals, Inc.(ATNM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Actinium Pharmaceuticals Inc (NYSE: ATNM) were down 24 percent to $1.29. Actinium priced 8 million shares at $1.25 per share.

    Shineco Inc (NASDAQ: TYHT) was down, falling around 32 percent to $19.50. On Wednesday, Shineco priced IPO at $4.50 per share.

investing in the stock market: International Speedway Corporation(ISCA)

Advisors’ Opinion:

  • [By Monica Gerson]

    International Speedway Corp (NASDAQ: ISCA) is projected to report its quarterly earnings at $0.41 per share on revenue of $146.09 million. International Speedway shares declined 1.65 percent to close at $36.26 yesterday.

  • [By Monica Gerson]

    International Speedway Corp (NASDAQ: ISCA) is estimated to report its quarterly earnings at $0.41 per share on revenue of $146.09 million.

    Mitcham Industries, Inc. (NASDAQ: MIND) is projected to post a quarterly loss at $0.36 per share on revenue of $10.99 million.

investing in the stock market: PCM, Inc.(PCMI)

Advisors’ Opinion:

  • [By Lisa Levin]

    PCM Inc (NASDAQ: PCMI) was down, falling around 26 percent to $14.63. PCM reported Q2 adjusted earnings of $0.47 per share on sales of $560.1 million.

investing in the stock market: Lucas Energy, Inc.(LEI)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    The Interior Department is in charge of managing regulations around oil and gas drilling around the nation. Currently, the favorite appears to be Forrest Lucas, the 74-year-old founder of Lucas Energy Inc. (NYSEMKT: LEI). A career energy executive, Lucas recently told Investors Business Daily that he would be interested in the job because “it’s a very important position and you need to have someone in there who knows what they’re doing.” However, Lucas has never actually met Trump in person.

Top 10 Blue Chip Stocks For 2018

On Wednesday, stocks recovered following the worst day overall since October. The gains were led by the technology sector, which in many cases reversed following their worst day of the year on Tuesday.

However, despite the tech rebound, the blue chips lagged pulling the Dow Jones Industrial Average down less than 0.1%. Nike Inc (NYSE:NKE), a Dow component, fell 7.1%, pulled lower by a lackluster outlook for sales growth.

The technology sector of the S&P 500 rose 0.8%, its biggest gain in three weeks. The Nasdaq, which is tech heavy, rose 0.5%, and the 500 jumped chiefly on gains by technology giants Microsoft Corporation (NASDAQ:MSFT), up 1.3%, Apple Inc. (NASDAQ:AAPL), up 1.1%, and Facebook Inc (NASDAQ:FB), up 1.1%. The PHLX Semiconductor Index (NASDAQ:SOXX) did its part by gaining 1.1%.

Crude oil (WTI) fell 0.4% as data showed that stockpiles of crude hit a new record high. Spot WTI closed at $48.04 per barrel for a fall of 11% so far in March.

At the close, the Dow Jones Industrial Average fell 7 points at 20,661, the S&P 500 rose 4 to 2,348, the Nasdaq gained 28 points to close at 5,822, and the Russell 2000 fell a point to 1,346. The NYSE ‘s primary exchange traded 899 million shares with total volume of 3.5 billion shares, and the Nasdaq crossed 1.8 billion shares. On the Big Board, advancers exceeded decliners by 1.1-to-1, and on the Nasdaq, decliners led by 1.3-to-1. Blocks on the NYSE fell to 6,935 from 7,804 on Tuesday.

Top 10 Blue Chip Stocks For 2018: Teva Pharmaceutical Industries Limited(TEVA)

Advisors’ Opinion:

  • [By Chris Lange]

    Look for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) second-quarter results on Thursday. The consensus earnings estimate is $1.07 per share, on $5.73 billion in revenue. The shares were last seen at $32.34. The consensus price target is $36.91, and the 52-week trading range is $27.60 to $55.79.

  • [By Dan Caplinger]

    Momenta Pharmaceuticals soared 25% after the biotechnology company won a lawsuit over alleged patent infringement. A Delaware federal district court found that four patents held by Teva Pharmaceutical (NYSE:TEVA) were invalid, opening the door for Momenta to offer its own competing version of a key drug. Momenta CEO Craig Wheeler provided details in his praise of the decision, noting that it “further bolsters our confidence in the potential for us to offer multiple sclerosis patients a more affordable generic version of Copaxone 40 mg following regulatory approval.” Momenta still has to get past some additional hurdles, but investors are hopeful that the path forward is clearer.

  • [By WWW.MONEYSHOW.COM]

    Opioid drug abuse has become a national epidemic; Teva Pharmaceutical Industries Limited (TEVA) has just developed a drug that could potentially deliver pain relief without the scourge of addiction, suggests Jimmy Mengel, editor of The Crow’s Nest.

Top 10 Blue Chip Stocks For 2018: Tenneco Inc.(TEN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of auto-part makers like Delphi Automotive (DLPH), BorgWarner (BWA), and Tenneco (TEN) are getting killed today, ostensibly due to an article in Automotive News. Wells Fargo’s Richard Kwas and team think Tesla Motors (TSLA) and its Model 3 deserve at least some of the blame:

Top 10 Blue Chip Stocks For 2018: Brookfield Renewable Powerr Fund(BEP)

Advisors’ Opinion:

  • [By Federico Zaldua]

    I expect the Brookfield Group of Companies, which is composed of no fewer than 15 publicly traded entities, to be very active acquisitive in the near-term future. Here I focus my attention on three members of the Brookfield Group that are going to be the most active with M&A. While Brookfield Asset Management (BAM) will concentrate its M&A efforts into all geographies and all asset classes, Brookfield Renewable Energy Partners (BEP) and Brookfield Infrastructure Partners (BIP) will concentrate on their respective industries. Let’s see whether you should go long on any of this separate -although related – entities.

    Good Operational Performance

    Brookfield Asset Management, held by Lou Simpson and Ron Baron, counts with a liquidity position of more than $5 billion at the parent and principal subsidiaries along with nearly $10 billion drawable private fund commitments. More importantly, the company has expressed its interest into using this liquidity to make acquisitions. Management clearly stated in its letter to shareholders:

Top 10 Blue Chip Stocks For 2018: Amphenol Corporation(APH)

Advisors’ Opinion:

  • [By Darren Williams] Although the entire cannabis space has quietly taken a hit of their own medicine in recent weeks and gone to sleep, don’t think for one second the entire space isn’t going to light up again soon. That’s just what they do, right? However, knowing who the pretenders are and knowing who the contenders are is really the challenge when it’s comes right down to it.
    First, anyone who claims to be a grower or a seller of cannabis can’t for one second ever make it as a public company right now, or can even legally consider being a public company for that matter, so you can scratch any of those right off your list. At least here in the U.S. anyway, because Canada is already well ahead of the curve having legalized it for medicinal purposes already.
    More importantly, full legalization of marijuana in Canada appears to be on track for July 2018, which will make Canada just the second nation in the world after Uruguay to completely legalize the cultivation, sale and possession of the drug for medical and recreational purposes.
    Regardless, the best time to buy any stocks in a hot growth sector is when either everyone has forgotten about them, or when the overall market landscape has turned bearish, which has yet to happen. However, the former seems to be the case for the cannabis space, despite some very favorable state legislation last Fall.
    For now, as long as you have a license issued by Health Canada, you’re good to go, so there are some stocks trading in Canada already who are well on their way to making some green for investors. Canopy Growth Corporation (TSE: WEED), formerly Tweed Marijuana Inc., is a medical marijuana company based in Smiths Falls, Ontario. Aurora Cannabis Inc. (CVE: ACB), which is engaged in the production and sale of medical cannabis. There’s also Aphria Pharmaceutical Company (TSE: APH), which also is engaged in producing and selling medical marijuana through retail sales and wholesale channels.
    There are many more, but those are just a
  • [By Lee Jackson]

    This is the top pick in the sector and has remained a favorite at RBC for some time.Amphenol Corp. (NYSE: APH) is one of the worlds largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors, interconnect systems, antennas, sensors and sensor-based products and coaxial and high-speed specialty cable.

Top 10 Blue Chip Stocks For 2018: Yingli Green Energy Holding Company Limited(YGE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) is expected to post a quarterly loss at $1.48 per share on revenue of $372.30 million.

    Ameren Corp (NYSE: AEE) is estimated to post its quarterly earnings at $0.38 per share on revenue of $1.51 billion.

  • [By Spencer Israel]

    Axiom Capital Managing Director Gordon Johnson upgraded the entire alternative energy sector from Market Underweight to Market Overweight and upgraded SolarCity Corp (NASDAQ: SCTY) from Sell to Hold and Trina Solar Limited (ADR) (NYSE: TSL), Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) and JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) from Sell to Buy.

  • [By Wayne Duggan]

    Despite the potentially positive recent developments for solar investors, Johnson remains extremely bearish on solar stocks. Axiom maintains Sell ratings on the following U.S.-listed names:

    JA Solar Holdings Co. Ltd. (ADR) (NASDAQ: JASO) Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) Solaredge Technologies Inc (NASDAQ: SEDG) Canadian Solar Inc. (NASDAQ: CSIQ)

    Related Link: Politics Here And Abroad: Muted Market Volume Amid Comey’s Testimony And UK’s Election
    _______
    Image Credit: Screengrab from “Trump Makes Statement On Paris Accord” By The White House [Public domain], via Wikimedia Commons

Top 10 Blue Chip Stocks For 2018: iShares MSCI All Peru Capped ETF (EPU)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    ARGT, the lone exchange traded fund dedicated to Argentine equities, is up 19.6 percent year-to-date. That is good for the second-best showing among Latin America single-country ETFs, trailing only the iShares MSCI Capped Peru Index Fund (NYSE: EPU).

  • [By Andrew Efimoff] Related Some Positive Indexing News For A Frontier Markets ETF Why The Frontier Markets ETF Slumped Last Year Status Quo Decisions Would Bode Well For PAK ETF (Seeking Alpha)
    Related EPU Peru ETF Confronts Politics Commodities Call For The Colombia ETF Graċ¸½a Y Montero May Have Peaked In 2016 (Seeking Alpha) Gainers Pakistan: Global XMSCI Pakistan ETF (NYSE: PAK) is up 5.67 percent after receiving MSCI’s Emerging Markets Index approval. Peru: iShares MSCI All Peru Capped Index Fund(NYSE: EPU) is up 2.15 percent after Kuzynski won Peru’s nail-biting election. Philippines: iShares MSCI Philippines Investable(NYSE: EPHE) is up 2.21 percent after Macquarie Research said President Elect Rodrigo Duterte would lift the Pilipino property market. India: iShares MSCI India ETF (NYSE: INDA) is up 1.96 percent after India’s government relaxed regulation, making it easier for domestic airlines to fly overseas.

    Related Link: Some Positive Indexing News For A Frontier Markets ETF

Top 10 Blue Chip Stocks For 2018: Actinium Pharmaceuticals, Inc.(ATNM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Actinium Pharmaceuticals Inc (NYSE: ATNM) were down 24 percent to $1.29. Actinium priced 8 million shares at $1.25 per share.

    Shineco Inc (NASDAQ: TYHT) was down, falling around 32 percent to $19.50. On Wednesday, Shineco priced IPO at $4.50 per share.

Top 10 Blue Chip Stocks For 2018: PCM, Inc.(PCMI)

Advisors’ Opinion:

  • [By Lisa Levin]

    PCM Inc (NASDAQ: PCMI) was down, falling around 26 percent to $14.63. PCM reported Q2 adjusted earnings of $0.47 per share on sales of $560.1 million.

Top 10 Blue Chip Stocks For 2018: SPDR S&P Biotech ETF (XBI)

Advisors’ Opinion:

  • [By ]

    After sneaking lower to begin the new trading week, the SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels.

  • [By WWW.KIPLINGER.COM]

    Theres been follow-up, too: Valeant Pharmaceuticals Intl Inc (VRX) had to face the Senate in April for aggressively hiking prices on its drugs. Now Mylan NV (MYL) is answering to the government soon after a story showed that EpiPen prices have rocketed 400% since 2008 with no significant improvements to the treatment. This scandal, too, is rocking biotechs including (Link]recommendation SPDR S&P Biotech ETF (XBI).

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.

Top 10 Blue Chip Stocks For 2018: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

best way to invest

Tesla’s non-GAAP hand is filled with aces, even where previously SolarCity reported deuces.

This is a story about how non-GAAP metrics, flexible as they are, can be changed in real time to provide a better-looking picture for the same reality. This is extremely rare, of course, because it’s so obvious.

However, as we will see, it just happened with Tesla (NASDAQ:TSLA), and there’s no doubt the reality the non-GAAP measure represents is, indeed, the same reality. Meanwhile, regulators somewhere seem to be looking the wrong way. Here we go.

A Bit Of Background

best way to invest: Vanguard Mega Cap Growth ETF (MGK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Three of Vanguard's mega-cap equity ETFs now sport annual expense ratios of 0.07 percent, down from 0.09 percent. Those ETFs are the Vanguard Mega Cap ETF (NYSE: MGC), Vanguard Mega Cap 300 Growth Index ETF (NYSE: MGK) and the Vanguard Mega Cap Value Index ETF (NYSE: MGV).

best way to invest: PCM, Inc.(PCMI)

Advisors’ Opinion:

  • [By Lisa Levin]

    PCM Inc (NASDAQ: PCMI) was down, falling around 26 percent to $14.63. PCM reported Q2 adjusted earnings of $0.47 per share on sales of $560.1 million.

best way to invest: The NeutriSci International (NU)

Advisors’ Opinion:

  • [By Matthew Briar]

    Indeed, it’s also garnered interest from business partners. In November, Lexaria Bioscience and NeutriSci International Inc (CVE:NU) jointly announced they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line. In January, the duo announced it had finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

  • [By Matthew Briar]

    Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).

    Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.

    It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp

  • [By Bryan Murphy]

    In the grand scheme of things it shouldn’t be surprising, though odds are good at least a few people are surprised at how quickly it happened. That is, health supplement and healthy-foods brand name NeutriSci International Inc (CVE:NU) and the developer of a cannabis-infusion technology — a means of packing more CBD into hemp oil — called Lexaria Bioscience Corp (OTCMKTS:LXRP) have finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

    The benefits of cannabidiol, found in hemp and marijuana, are relatively well understood by the market at this point. Cannabidiol can do a human body a lot of good, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. Pterostilbene is the lesser-known of the two components of the new tablet, but no less impressive and no less beneficial. Pterostilbene is known to combat high cholesterol, high blood pressure, and oxidative stress. Combining the two is a real one-two punch for the health-conscious.

    That’s what made November’s news so exciting… NeutriSci International has an established name and marketing channel, while Lexaria Bioscience has the science that makes hemp oil far more functional. Indeed, to fully appreciate the upside for LXRP, one has to embrace Lexaria’s science and why it matters.

    The bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short,

  • [By Matthew Briar]

    What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.

    Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.

    Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.

    Pterostilbene (found in blueberries, by the way) is o

best way to invest: Ring Energy, Inc.(REI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Ring Energy Inc (NYSE: REI) is projected to post a quarterly loss at $0.05 per share on revenue of $7.92 million.

    Gain Capital Holdings Inc (NYSE: GCAP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $100.39 million.